Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antibody Titers Clear all
Completed Phase 2 Interventional Results available

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

NCT05518487
View directory record Official record
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

NCT02139657
View directory record Official record
Conditions
Rabies
Interventions
RIG-C
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 31, 2026, 1:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational

A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis

NCT00288990
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational

COVID-19 Quantitative Antibody Titers & Booster Vaccinations

NCT05104359
View directory record Official record
Conditions
COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine
Interventions
Observational
Other
Lead sponsor
Epividian
Industry
Eligibility
18 Years and older
Enrollment
825 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 31, 2026, 1:53 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety Study of FluMist With and Without Ampligen

NCT01591473
View directory record Official record
Conditions
Influenza, Human
Interventions
Poly I:Poly C12U 50 ug, Poly I:Poly C12U 200 ug, Poly I:Poly C12U 500 ug, Poly I:Poly C12U 1250 ug, Placebo, FluMist
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 2 Interventional

Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

NCT00069316
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-IgG-am
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational

Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine

NCT00542776
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Immunosuppressed or Non-Immunosuppressed, Influenza Vaccine, Antibody Titers, Seroprotective Titers
Interventions
blood draw
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2008 · Synced Oct 31, 2026, 1:53 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

NCT02511002
View directory record Official record
Conditions
Post Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 1Phase 2 Interventional

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

NCT00478465
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
valganciclovir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to Influenza Vaccine in HIV-Infected Individuals

NCT00069914
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 1 Interventional

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

NCT00143741
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Atorvastatin (Lipitor)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational

Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load

NCT00025922
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

NCT02500511
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
NmVac4-A/C/Y/W-135-DT™
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 31, 2026, 1:53 PM EDT
Completed No phase listed Observational

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

NCT02006784
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Challenge Infection of Healthy Adult Volunteers With RSV A2

NCT03388645
View directory record Official record
Conditions
Upper Respiratory Tract Infections
Interventions
10^6.3 PFU of RSV A2, 10^7 PFU of RSV A2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 31, 2026, 1:53 PM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 31, 2026, 1:53 PM EDT